Big Picture – A Deep Dive Examination of Shield Therapeutics PLC
Shield Therapeutics PLC Snapshot
Feraccru® (Ferric Maltol) is a stable, non-salt, oral formulation of ferric iron, which has a novel mechanism of action compared to salt-based oral iron therapies.
For further information on Feraccruhere.
Pipeline product candidates
PT20 is a novel iron-based phosphate binder that we are developing for the treatment of hyperphosphatemia. The integration of adipic acid to form PT20 increases the phosphate binding capacity by a factor of three, compared to the unmodified iron oxide. The manufacturing process also results in particles of a very small size, which maximises the surface available for phosphate binding.
PT20 is exclusively licensed from the Medical Research Council in the United Kingdom.
PT30 and PT40
PT30 is a novel IV iron formulation and PT40 is being developed to be the first generic version of iron sucrose.
Chief Executive Officer and Co-Founder
Hans Peter Hasler
Dr Mark Sampson
Chief Medical Officer
Dr Jackie Mitchell
VP Regulatory Affairs and Quality
Director of Product Supply and Commercial Alliances
Senior Legal Counsel and Company Secretary